The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression

Jenny Lam, Heike Wulff

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

The voltage-gated Kv1.3 and the calcium-activated KCa3.1 potassium channel modulate many calcium-dependent cellular processes in immune cells, including T-cell activation and proliferation and have therefore been proposed as novel therapeutic targets for immunomodulation. Kv1.3 is highly expressed in CCR7 - effector memory T cells and is emerging as a target for T-cell-mediated diseases like multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, allergic contact dermatitis, and psoriasis. In contrast, KCa3.1 is expressed in CCR7+ naive and central memory T cells, as well as in mast cells, macrophages, dedifferentiated vascular smooth muscle cells, fibroblasts, vascular endothelium, and airway epithelium. Given this expression pattern, KCa3.1 is a potential therapeutic target for conditions ranging from inflammatory bowel disease, multiple sclerosis, arthritis, and asthma to cardiovascular diseases such as atherosclerosis and post-angioplasty restenosis. Results from animal studies have been supportive of the therapeutic potential of both Kv1.3 and KCa3.1 blockers and have also not shown any toxicities associated with pharmacological Kv1.3 and KCa3.1 blockade. To date, two compounds targeting Kv1.3 are in preclinical development, but so far, no Kv1.3 blocker has advanced into clinical trials. KCa3.1 blockers, on the other hand, have been evaluated in clinical trials for sickle cell anemia and exercise-induced asthma, but have so far not shown efficacy. However, the trial results support KCa3.1 as a safe therapeutic target and hopefully will enable clinical trials for other medical conditions that might benefit from KCa3.1 blockade.

Original languageEnglish (US)
Pages (from-to)573-584
Number of pages12
JournalDrug Development Research
Volume72
Issue number7
DOIs
StatePublished - Nov 2011

Fingerprint

Kv1.3 Potassium Channel
Immunosuppression
Lymphocytes
T-Lymphocytes
Clinical Trials
Multiple Sclerosis
Exercise-Induced Asthma
Calcium-Activated Potassium Channels
Allergic Contact Dermatitis
Immunomodulation
Vascular Endothelium
Sickle Cell Anemia
Therapeutics
Type 1 Diabetes Mellitus
Vascular Smooth Muscle
Angioplasty
Inflammatory Bowel Diseases
Psoriasis
Mast Cells
Arthritis

Keywords

  • immunosuppression
  • KCa3.1
  • Kv1.3
  • PAP-1
  • potassium channel
  • TRAM-34

ASJC Scopus subject areas

  • Drug Discovery

Cite this

The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression. / Lam, Jenny; Wulff, Heike.

In: Drug Development Research, Vol. 72, No. 7, 11.2011, p. 573-584.

Research output: Contribution to journalArticle

@article{25f18dc0bbf44227a4f4e1702457ec21,
title = "The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression",
abstract = "The voltage-gated Kv1.3 and the calcium-activated KCa3.1 potassium channel modulate many calcium-dependent cellular processes in immune cells, including T-cell activation and proliferation and have therefore been proposed as novel therapeutic targets for immunomodulation. Kv1.3 is highly expressed in CCR7 - effector memory T cells and is emerging as a target for T-cell-mediated diseases like multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, allergic contact dermatitis, and psoriasis. In contrast, KCa3.1 is expressed in CCR7+ naive and central memory T cells, as well as in mast cells, macrophages, dedifferentiated vascular smooth muscle cells, fibroblasts, vascular endothelium, and airway epithelium. Given this expression pattern, KCa3.1 is a potential therapeutic target for conditions ranging from inflammatory bowel disease, multiple sclerosis, arthritis, and asthma to cardiovascular diseases such as atherosclerosis and post-angioplasty restenosis. Results from animal studies have been supportive of the therapeutic potential of both Kv1.3 and KCa3.1 blockers and have also not shown any toxicities associated with pharmacological Kv1.3 and KCa3.1 blockade. To date, two compounds targeting Kv1.3 are in preclinical development, but so far, no Kv1.3 blocker has advanced into clinical trials. KCa3.1 blockers, on the other hand, have been evaluated in clinical trials for sickle cell anemia and exercise-induced asthma, but have so far not shown efficacy. However, the trial results support KCa3.1 as a safe therapeutic target and hopefully will enable clinical trials for other medical conditions that might benefit from KCa3.1 blockade.",
keywords = "immunosuppression, KCa3.1, Kv1.3, PAP-1, potassium channel, TRAM-34",
author = "Jenny Lam and Heike Wulff",
year = "2011",
month = "11",
doi = "10.1002/ddr.20467",
language = "English (US)",
volume = "72",
pages = "573--584",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The lymphocyte potassium channels Kv1.3 and KCa3.1 as targets for immunosuppression

AU - Lam, Jenny

AU - Wulff, Heike

PY - 2011/11

Y1 - 2011/11

N2 - The voltage-gated Kv1.3 and the calcium-activated KCa3.1 potassium channel modulate many calcium-dependent cellular processes in immune cells, including T-cell activation and proliferation and have therefore been proposed as novel therapeutic targets for immunomodulation. Kv1.3 is highly expressed in CCR7 - effector memory T cells and is emerging as a target for T-cell-mediated diseases like multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, allergic contact dermatitis, and psoriasis. In contrast, KCa3.1 is expressed in CCR7+ naive and central memory T cells, as well as in mast cells, macrophages, dedifferentiated vascular smooth muscle cells, fibroblasts, vascular endothelium, and airway epithelium. Given this expression pattern, KCa3.1 is a potential therapeutic target for conditions ranging from inflammatory bowel disease, multiple sclerosis, arthritis, and asthma to cardiovascular diseases such as atherosclerosis and post-angioplasty restenosis. Results from animal studies have been supportive of the therapeutic potential of both Kv1.3 and KCa3.1 blockers and have also not shown any toxicities associated with pharmacological Kv1.3 and KCa3.1 blockade. To date, two compounds targeting Kv1.3 are in preclinical development, but so far, no Kv1.3 blocker has advanced into clinical trials. KCa3.1 blockers, on the other hand, have been evaluated in clinical trials for sickle cell anemia and exercise-induced asthma, but have so far not shown efficacy. However, the trial results support KCa3.1 as a safe therapeutic target and hopefully will enable clinical trials for other medical conditions that might benefit from KCa3.1 blockade.

AB - The voltage-gated Kv1.3 and the calcium-activated KCa3.1 potassium channel modulate many calcium-dependent cellular processes in immune cells, including T-cell activation and proliferation and have therefore been proposed as novel therapeutic targets for immunomodulation. Kv1.3 is highly expressed in CCR7 - effector memory T cells and is emerging as a target for T-cell-mediated diseases like multiple sclerosis, rheumatoid arthritis, type-1 diabetes mellitus, allergic contact dermatitis, and psoriasis. In contrast, KCa3.1 is expressed in CCR7+ naive and central memory T cells, as well as in mast cells, macrophages, dedifferentiated vascular smooth muscle cells, fibroblasts, vascular endothelium, and airway epithelium. Given this expression pattern, KCa3.1 is a potential therapeutic target for conditions ranging from inflammatory bowel disease, multiple sclerosis, arthritis, and asthma to cardiovascular diseases such as atherosclerosis and post-angioplasty restenosis. Results from animal studies have been supportive of the therapeutic potential of both Kv1.3 and KCa3.1 blockers and have also not shown any toxicities associated with pharmacological Kv1.3 and KCa3.1 blockade. To date, two compounds targeting Kv1.3 are in preclinical development, but so far, no Kv1.3 blocker has advanced into clinical trials. KCa3.1 blockers, on the other hand, have been evaluated in clinical trials for sickle cell anemia and exercise-induced asthma, but have so far not shown efficacy. However, the trial results support KCa3.1 as a safe therapeutic target and hopefully will enable clinical trials for other medical conditions that might benefit from KCa3.1 blockade.

KW - immunosuppression

KW - KCa3.1

KW - Kv1.3

KW - PAP-1

KW - potassium channel

KW - TRAM-34

UR - http://www.scopus.com/inward/record.url?scp=82155185368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155185368&partnerID=8YFLogxK

U2 - 10.1002/ddr.20467

DO - 10.1002/ddr.20467

M3 - Article

AN - SCOPUS:82155185368

VL - 72

SP - 573

EP - 584

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 7

ER -